Abstract
Objective Cancer is comorbidity, which can lead to progressive worsening of Covid-19 with increased mortality. This is a systematic review and meta-analysis to get evidence of adverse outcomes of Covid-19 in gynecologic cancer.
Methods Searches through PubMed, Google Scholar, ScienceDirect, and medRxiv to find articles on the outcome of gynecologic cancer with Covid-19 (24 July 2021-19 February 2022). Newcastle-Ottawa Scale tool used to evaluate the quality of included studies. Pooled odds ratio (OR), 95% confidence interval (CI), random-effects model were presented. This study was registered to PROSPERO (CRD42021256557).
Results We accepted 49 studies with (1994 gynecologic cancer with Covid-19). Covid-19 infection was lower in gynecologic cancer vs hematologic cancer (OR 0.71, CI 0.56-0.89, p 0.003). Severe Covid and death were lower in gynecologic cancer vs lung and hematologic cancer (OR 0.36, CI 0.16-0.80, p 0.01), (OR 0.26, CI 0.10-0.67 p 0.005), (OR 0.52, CI 0.43-0.63, p <0.0001), (OR 0.65, CI 0.49-0.87, p 0.003) respectively. Increased Covid death is seen in gynecologic cancer vs breast, non-covid cancer, and non-cancer covid (OR 1.51, CI 1.20-1.90, p 0.0004), (OR 12.21, CI 8.39-17.77, p <0.0001), (OR 3.06, CI 2.32-4.04, p <0.0001) respectively.
Conclusion Gynecologic cancer had increased Covid-19 adverse outcomes compared to non-cancer, breast cancer, non-metastatic, and Covid-19 negative population. Gynecologic cancer had lowered Covid-19 adverse outcomes compared to other cancer types, lung cancer, and hematologic cancer. Lack of age and comorbidities stratification due to limited data were limitations. These findings may aid health policies and services during the ongoing global pandemic.
Synopsis This is a systematic review and meta analysis study that presents pooled evidence of outcome among gynecologic cancer patients infected with the Covid-19 infection. We manage to gather 49 studies involving 1994 gynecologic cancer patients with Covid-19, 220967 non cancer patients with Covid-19, 4080990 cancer patients without Covid-19 and 28658 non gynecologic cancer patients with Covid-19 for analysis. Meta analysis shows reduction of Covid-19 death with gynecologic cancer patients vs overall other cancer, lung cancer, and hematologic cancer (OR 0.84, CI 0.72-0.97, p 0.02), (OR 0.52, CI 0.43-0.63, p <0.0001), (OR 0.65, CI 0.49-0.87, p 0.003) respectively. On the contrary, increased risk of Covid-19 death occur to gynecologic cancer patients vs infected non cancer, non Covid cancer patients, and infected breast cancer patients (OR 3.06, CI 2.32-4.04, p <0.0001), (OR 12.21, CI 8.39-17.77, p <0.0001), (OR 1.51, CI 1.20-1.90, p 0.0004) respectively. Analysis from SARS-Cov-2 infection shows lower infection with gynecologic cancer patients vs hematologic cancer cohort (OR 0.71, CI 0.56-0.89, p 0.003). We hope the result of this meta analysis will be useful to providers practicing in cancer centers and tertiary cancer referral hospitals thus better practices and care services given to gynecologic cancer patients infected with / without the Covid-19 during the ongoing global pandemic can be achieved.
To our knowledge this is the first systematic review and meta analysis which emphasizes on reporting the outcome of gynecologic cancer patients with the Covid-19 infection. We also found no publication bias across 49 studies we have gathered and used as meta analysis data.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=256557
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Disclaimers: None Declared.
Data Availability
The report of the following are publicly available and they can be found in the supplementary material.